Back to All

Diaceutics announces the issuance of share options

6 April, 2020

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issuance of share options over ordinary shares of 0.2p each in the Company (“Share Options”) to certain Directors, members of the Company’s senior management team and other key staff, pursuant to the Company’s Employee Share Option Plan (“ESOP”) established at the time of the Company’s admission to AIM. These awards are made in accordance with the Company’s long term incentive plan. Share Options were granted as follows:

NameNumber of Share Options grantedTotal no. of ordinary shares under option post grant% of existing issued share capitalGrant date
Peter Keeling, CEO180,000180,0000.26%3 April 2020
Philip White CFO180,000180,0000.26%3 April 2020
Ryan Keeling CIO180,000180,0000.26%3 April 2020
Damian Thornton COO and PDMR94,30498,5040.14%3 April 2020
Jordan Clark CCO and PDMR67,71471,9140.10%3 April 2020
Susanne Munksted PDMR62,27266,4720.10%3 April 2020
Other employees (72 persons with no individual in excess of 45,000 Share Options)665,955825,5551.19%No later than 20 April 2020

The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 126.5p per share which has been calculated by using the average mid-market closing price over the past five business days. Following the grant the total number of share options outstanding is 1,602,444, representing approximately 2.3% of the Company’s current issued share capital of 69,583,100.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny